LONDON, UK: Fusion Antibodies plc has entered into a commercial collaboration agreement with Eurofins Discovery, a leading provider of products and services to the drug discovery industry.
Eurofins is a Eurofins Scientific SE (EUFI.PA) group company. Pursuant to the Collaboration, Fusion will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins and onwards to their customers.
The collaboration is not expected to have a material impact on the Company’s earnings in the current financial year, however, the Directors of Fusion consider that it demonstrates a commitment by both parties to provide world-class scientific expertise, next-generation technology, and guidance to accelerate the delivery of the best possible antibody against a broad range of targets and therapeutic areas into the clinic for both parties.
As leading global innovation-driven and customer-focused providers of antibody development services, Fusion Antibodies and Eurofins Discovery share common values in the culture of collaboration and the pursuit of scientific excellence.
Richard Jones, CEO of Fusion Antibodies commented: “We’re delighted to enter into this commercial collaboration with Eurofins which leverages the respective expertise of both partners, delivering on both our strategic objectives as well as providing a full client service package.” www.fusionantibodies.com